These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9723428)

  • 21. Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report.
    Jirasiritham S; Khunprakant R; Techawathanawanna N; Jirasiritham S; Mavichak V
    Transplant Proc; 2010 Apr; 42(3):987-9. PubMed ID: 20430222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between Banff classification, acute renal rejection scores, and reversal of rejection.
    Gaber LW; Moore LW; Alloway RR; Flax S; Gaber AO
    Transplant Proc; 1995 Feb; 27(1):1019. PubMed ID: 7878784
    [No Abstract]   [Full Text] [Related]  

  • 23. Antibody therapy in steroid-resistant rejection.
    Waiser J; Budde K; Schreiber M; Böhler T; Löbermann LA; Neumayer HH
    Transplant Proc; 1998 Aug; 30(5):1778-9. PubMed ID: 9723279
    [No Abstract]   [Full Text] [Related]  

  • 24. Plasmapheresis, intravenous cytomegalovirus-specific immunoglobulin and reversal of antibody-mediated rejection in a pediatric renal transplant recipient: a case report.
    Furth S; Neu AM; Hart J; Zachary A; Colombani P; Fivush BA
    Pediatr Transplant; 1999 May; 3(2):146-9. PubMed ID: 10389137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylactic OKT3 monoclonal antibody versus antilymphocyte globulins: a prospective, randomized study in 148 first cadaver kidney grafts.
    Broyer M; Gagnadoux MF; Guest G; Arsan A; Beurton D; Revillon Y; Niaudet P
    Transplant Proc; 1993 Feb; 25(1 Pt 1):570-1. PubMed ID: 8438418
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy of a negative conversion trial and subsequent living donor kidney transplant outcome in recipients with a positive lymphocyte crossmatch.
    Huh KH; Kim SI; Joo DJ; Ju MK; Chang HK; Kim HJ; Kim YS; Kim MS
    Nephron Clin Pract; 2009; 111(1):c49-54. PubMed ID: 19052470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoglobulin i.v. high dose (IVIgHD): new therapy as a rescue treatment of grafted kidneys.
    Casadei D; Rial M; Raimondi E; Goldberg J; Argento J; Haas E
    Transplant Proc; 1996 Dec; 28(6):3290-1. PubMed ID: 8962275
    [No Abstract]   [Full Text] [Related]  

  • 28. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
    Shield CF
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
    [No Abstract]   [Full Text] [Related]  

  • 29. Antibody induction therapy in pancreas transplantation.
    Gruessner RW
    Transplant Proc; 1998 Jun; 30(4):1556-9. PubMed ID: 9636632
    [No Abstract]   [Full Text] [Related]  

  • 30. Monitoring of donor sensitization in kidney transplant recipients by flow cytometric crossmatch.
    Cinti P; Bachetoni A; Baiano V; Pretagostini R; Poli L; Berloco P; Renna Molajoni E; Cortesini R
    Transplant Proc; 1993 Dec; 25(6):3265-6. PubMed ID: 8266536
    [No Abstract]   [Full Text] [Related]  

  • 31. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection: analysis beyond 4 years.
    Sharma LC; Muirhead N; Lazarovits AI
    Transplant Proc; 1997; 29(1-2):323-4. PubMed ID: 9123021
    [No Abstract]   [Full Text] [Related]  

  • 32. Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts.
    Alamartine E; Bellakoul R; Berthoux F
    Transplant Proc; 1994 Feb; 26(1):273-4. PubMed ID: 8108975
    [No Abstract]   [Full Text] [Related]  

  • 33. Graft outcome in patients with biopsy-proven chronic renal allograft rejection.
    Peddi VR; Schroeder TJ; Weiskittel P; First MR
    Transplant Proc; 1999; 31(1-2):1308-9. PubMed ID: 10083584
    [No Abstract]   [Full Text] [Related]  

  • 34. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.
    Griñó JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Bover J; Torras J; Alsina J
    Transplant Proc; 1992 Feb; 24(1):39-41. PubMed ID: 1539329
    [No Abstract]   [Full Text] [Related]  

  • 35. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
    Norman DJ; Barry JM; Bennett WM; Munson JL; Meyer M; Henell K; Kimball J; Hubert B
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
    [No Abstract]   [Full Text] [Related]  

  • 36. CD2+, CD3+, and CD19+ depletion after a course of antithymocyte globulin for a steroid-resistant rejection.
    Grandtnerovà B; Mocikovà H; Kohutovà M
    Transplant Proc; 1997 Nov; 29(7):2958-9. PubMed ID: 9365628
    [No Abstract]   [Full Text] [Related]  

  • 37. Effectiveness of short-term OKT3 therapy in the treatment of steroid-resistant renal allograft rejection.
    Carvalho MF; Adoni T; Saggioro FP; Soares V
    Transplant Proc; 1998 Sep; 30(6):2876-7. PubMed ID: 9745607
    [No Abstract]   [Full Text] [Related]  

  • 38. Successful therapy of chronic renal allograft failure by enhanced immunosuppression.
    Kliem V; Tiroke T; Ehlerding G; Eberhard O; Behrend M; Frei U; Koch KM; Pichlmayr R; Brunkhorst R
    Transplant Proc; 1998 Jun; 30(4):1207-9. PubMed ID: 9636490
    [No Abstract]   [Full Text] [Related]  

  • 39. Rationale for OKT3 monoclonal antibody treatment in transplant patients.
    Norman DJ
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):1-3. PubMed ID: 8465414
    [No Abstract]   [Full Text] [Related]  

  • 40. The fate of renal allografts treated with OKT3 for steroid-resistant rejection.
    Veronese FV; Gonçalves LF; Vilarinho LL; Macedo VS; Manfro RC
    Transplant Proc; 1999 Nov; 31(7):3016-8. PubMed ID: 10578371
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.